Free Trial
NASDAQ:SRDX

Surmodics Q2 2025 Earnings Report

Surmodics logo
$29.46 +0.06 (+0.20%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$29.50 +0.04 (+0.12%)
As of 04/25/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Surmodics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.02
Beat/Miss
N/A
One Year Ago EPS
N/A

Surmodics Revenue Results

Actual Revenue
N/A
Expected Revenue
$32.23 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Surmodics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, April 30, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Surmodics Earnings Headlines

Surmodics publishes TRANSCEND trial data
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Barrington Sticks to Their Hold Rating for SurModics (SRDX)
SurModics (SRDX) Gets a Hold from Barrington
See More Surmodics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surmodics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surmodics and other key companies, straight to your email.

About Surmodics

Surmodics (NASDAQ:SRDX), together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

View Surmodics Profile

More Earnings Resources from MarketBeat